company background image
PIRS

Pieris Pharmaceuticals NasdaqCM:PIRS Stock Report

Last Price

US$1.56

Market Cap

US$116.1m

7D

-9.3%

1Y

-59.4%

Updated

11 Aug, 2022

Data

Company Financials +
PIRS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

PIRS Stock Overview

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs.

Pieris Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pieris Pharmaceuticals
Historical stock prices
Current Share PriceUS$1.56
52 Week HighUS$6.15
52 Week LowUS$1.54
Beta1.01
1 Month Change-18.75%
3 Month Change-8.77%
1 Year Change-59.38%
3 Year Change-68.16%
5 Year Change-66.31%
Change since IPO-40.00%

Recent News & Updates

Aug 10
Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications

Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications

The latest analyst coverage could presage a bad day for Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ), with the covering...

Aug 04

Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M

Pieris Pharmaceuticals press release (NASDAQ:PIRS): Q2 GAAP EPS of -$0.14 misses by $0.03. Revenue of $3.7M (+12.5% Y/Y) misses by $6.77M. Cash, equivalents, and investments totaled $80.9 million for the quarter ended June 30, 2022, compared to a cash and cash equivalents balance of $117.8 million for the quarter ended December 31, 2021.. Shares +4.95% PM.

Shareholder Returns

PIRSUS BiotechsUS Market
7D-9.3%1.2%1.3%
1Y-59.4%-23.0%-11.7%

Return vs Industry: PIRS underperformed the US Biotechs industry which returned -22.1% over the past year.

Return vs Market: PIRS underperformed the US Market which returned -11.6% over the past year.

Price Volatility

Is PIRS's price volatile compared to industry and market?
PIRS volatility
PIRS Average Weekly Movement7.9%
Biotechs Industry Average Movement12.5%
Market Average Movement7.8%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: PIRS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: PIRS's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2000133Steve Yoderhttps://www.pieris.com

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers.

Pieris Pharmaceuticals, Inc. Fundamentals Summary

How do Pieris Pharmaceuticals's earnings and revenue compare to its market cap?
PIRS fundamental statistics
Market CapUS$116.07m
Earnings (TTM)-US$41.51m
Revenue (TTM)US$27.19m

4.3x

P/S Ratio

-2.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PIRS income statement (TTM)
RevenueUS$27.19m
Cost of RevenueUS$60.31m
Gross Profit-US$33.12m
Other ExpensesUS$8.39m
Earnings-US$41.51m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.56
Gross Margin-121.83%
Net Profit Margin-152.68%
Debt/Equity Ratio0%

How did PIRS perform over the long term?

See historical performance and comparison